bluebird bio (NASDAQ: BLUE) reported Q3 EPS of ($3.16), $0.56 worse than the analyst estimate of ($2.60). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $35.4 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.